EHA 2025 | Updated results from DREAMM-8: belamaf plus pomalidomide and dexamethasone in R/R myeloma

The DREAMM-8 study, which has been published a few months ago, is a prospective randomized trial which is comparing the activity of pomalidomide, bortezomib, and dexamethasone as the control arm with the combination of belantamab mafodotin with pomalidomide and dexamethasone as the investigational arm. The importance of this study is that it includes patients who have been pre-treated with lenalidomide, and this is the majority of the patients with myeloma today, but also it included patients who were pre-treated with anti-CD38 monoclonal antibody, daratumumab or isatuximab, and this is an increasing patient population based on the current standard care. 

In this study, we report in this meeting that there is an improved progression-free survival and the median is 32 months, meaning that with a combination of belantamab given on an outpatient basis, you can achieve an almost three-year median progression-free survival in patients with myeloma who have been pre-treated and most of them are resistant to lenalidomide but also to daratumumab or isatuximab. 

The toxicity of the combination was as expected, with ocular issues that are associated with belantamab, but with appropriate dose adjustment and holding belantamab until there is a recovery of the high toxicity, the majority of the patients remained on study and actually were able to benefit from this very active combination.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.